WO2000032591A1 - Process for the preparation of paroxetine hydrochloride - Google Patents

Process for the preparation of paroxetine hydrochloride Download PDF

Info

Publication number
WO2000032591A1
WO2000032591A1 PCT/GB1999/003961 GB9903961W WO0032591A1 WO 2000032591 A1 WO2000032591 A1 WO 2000032591A1 GB 9903961 W GB9903961 W GB 9903961W WO 0032591 A1 WO0032591 A1 WO 0032591A1
Authority
WO
WIPO (PCT)
Prior art keywords
paroxetine hydrochloride
acetone
process according
acetone solvate
microns
Prior art date
Application number
PCT/GB1999/003961
Other languages
French (fr)
Inventor
Andrew Simon Craig
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to AU13964/00A priority Critical patent/AU1396400A/en
Publication of WO2000032591A1 publication Critical patent/WO2000032591A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to a process for the preparation of a pharmaceutically active compound and intermediates thereof, and to the use of the active compound in therapy.
  • this invention is concerned with a new process for the preparation of paroxetine chloride acetone solvate and its use to prepare a crystalline anhydrate form of paroxetine hydrochloride.
  • Paroxetine hydrochloride has been described in the literature as a crystalline hemihydrate (see EP-A-0223403 of Beecham Group) and as various crystalline anhydrate forms (see WO96/24595 of SmithKline Beecham).
  • WO96/24595 describes the preparation of paroxetine hydrochloride acetone solvate which is a useful intermediate for the preparation of paroxetine hydrochloride anhydrate Form A.
  • paroxetine hydrochloride acetone solvate When prepared conventionally by crystallisation from anhydrous acetone, paroxetine hydrochloride acetone solvate has poor stirring properties, and is difficult to isolate, wash, and dry.
  • This invention provides processes for the preparation of paroxetine hydrochloride acetone solvate in a form which is more easily desolvated than paroxetine hydrochloride acetone solvate prepared in a conventional manner, and hence more suitable for commercial manufacturing processes.
  • a process for preparing crystalline paroxetine hydrochloride acetone solvate which comprises providing a solution of paroxetine hydrochloride in acetone, and crystallising paroxetine hydrochloride acetone solvate under conditions of intense insonation.
  • insonation is carried out during slow cooling through the metastable zone, and is maintained during cooling to ambient temperature.
  • These conditions provide a continuous flux of freshly generated nuclei, and result in crystallisation of paroxetine hydrochloride acetone solvate in a modified crystal habit which is easy to stir, wash and filter, and surprisingly is more readily desolvated than conventionally crystallised paroxetine hydrochloride acetone solvate.
  • Suitably crystallization is carried out in a vessel provided with one or more high intensity ultrasonic probes, for example with titanium alloy resonant horns which enable acoustic energy to be coupled to the crystallizing medium at a frequency of 20 kHz and an amplitude of 12 microns or more, and with a device that modifies the power output according to the acoustic parameters of the load.
  • Insonation may be intermittent, limited to part of the apparatus, or discontinued once sufficient nuclei have been generated.
  • rapid crystallisation onto a dense flux of freshly generated nuclei may be achieved by causing rapid crystallisation in a continuous flow crystallisation apparatus.
  • the crystallisation may be achieved by bringing together two liquid streams, for example a solution of paroxetine hydrochloride in acetone and an anti-solvent such as hexane or heptane, or by rapid cooling of a single solvent stream, or by insonation of a saturated solvent stream, or by a combination of some or all of these techniques.
  • generation of nuclei and crystallisation takes place in a reaction zone, which may vary from a specially designed vortex mixer to a simple Y-tube.
  • a process for crystallising paroxetine hydrochloride acetone solvate with modified habit from a solution of paroxetine hydrochloride in acetone in the presence of a dense flux of nuclei supplied by the addition of seeds is obtained from a wide range of paroxetine hydrochloride solvates such as, for example, the solvate with pyridine, acetic acid, p- xylene, N.N'-dimethylformamide, chloroform, dichloromethane.
  • the efficiency of external seeding may be greatly increased by very vigorous stirring, since secondary nuclei are generated by attrition of larger seed crystals, resulting in an increased flux of suitable nuclei.
  • a suffficient flux of nuclei may be generated by particularly vigorous stirring alone, although this procedure is unlikely to be as effective unless the crystallisation vessel is routinely used for the crystallisation of paroxetine hydrochloride acetone solvate and so is in effect saturated with seed crystals.
  • Suitable apparatus includes stirrers designed to operate at high torque with high shear rate and vessels with optimal hydrodynamic design including the use of baffles and bladed stirrers.
  • a suitable concentration of paroxetine hydrochloride in acetone is one part in from 4 to 40 volumes of acetone, preferably from 10 to 30 volumes, and more preferably from 15 to 25 volumes.
  • the acetone is anhydrous to suppress formation of paroxetine hydrochloride hemihydrate.
  • Suitable procedures for preparing paroxetine hydrochloride for dissolution in acetone for use in the process of this invention include those mentioned in US Patents 4.009.196; 4,721,723; 4,902,801 ; 4,861,893 and 5,039,803.
  • crystallisation may be assisted by conventional techniques such as cooling, or removing solvent by evaporation or distillation.
  • the crystalline paroxetine hydrochloride acetone solvate of modified crystal habit obtainable by the process of this invention is a different crystalline form from the previously known product. This novel product forms another aspect of this invention.
  • Paroxetine hydrochloride acetone solvate crystals prepared conventionally are large and long, typically with most of the material in the form of crystals in excess of 300 microns in length, with a length-to-width ratio in excess of 40: 1 , and a volume by for example laser light scattering, of 20,000 cubic microns or more.
  • most of the material is in crystals less than 100 microns long, preferably below 75 microns, and more preferably below 50 microns, and with a length-to-width ratio below 20:1, preferably below 15:1 and more preferably below 10: 1, and with a volume below 5,000 cubic microns, preferably below 2,500 cubic microns and more preferably below
  • paroxetine hydrochloride acetone solvate of modified habit in which the mean distance between crystal facets characterised by the Miller indices (0, 1, 0) and (0, ⁇ ⁇ , 0) in a monoclinic crystal system. P2, space group is minimised, and is preferably below 100 microns.
  • paroxetine hydrochloride acetone solvate with these characteristics may be processed and desolvated more easily than conventionally produced paroxetine hydrochloride acetone solvate.
  • the crystallisation process may include if necessary isolating the crystals, optionally washing and drying to remove surface solvent.
  • the crystalline solvate is used as a feed material for desolvation to obtain paroxetine hydrochloride anhydrates, especially the Form A anhydrate.
  • the present invention provides a process for preparing a crystalline anhydrate of paroxetine hydrochloride by heating crystalline acetone solvate obtainable by the process of this invention to remove bound acetone.
  • Desolvation is conveniently carried out by heating in an oven, preferably in vacuo, suitably at a temperature of about 60°C.
  • the resultant anhydrate desirably contains less than 3% of acetone, preferably less than 1%, more preferably less than 0.5%, and most preferably less than 0.1%.
  • the crystalline anhydrate is the Form A anhydrate of paroxetine hydrochloride.
  • the crystalline paroxetine hydrochloride anhydrate obtainable by this invention may be used in therapy in formulations described in EP-A-0223403 or WO 96/00477.
  • paroxetine hydrochloride anhydrate of this invention include treatment of: alcoholism, anxiety, depression, obsessive compulsive disorder (OCD), panic disorder, chronic pain, obesity, senile dementia, migraine, bulimia, anorexia, social phobia, pre-menstrual syndrome (PMS), adolescent depression, trichotillomania. dysthymia, and substance abuse, referred to below as "the disorders”.
  • anhydrate obtainable by the present invention is applied to the treatment of depression, OCD and panic.
  • compositions prepared in accordance with this invention are usually adapted for oral administration, but formulations for dissolution for parental administration are also within the scope of this invention.
  • the composition is usually presented as a unit dose composition containing from 1 to 200 mg of active ingredient calculated on a free base basis, more usually from 5 to 100 mg, for example 10 to 50mg such as 10, 12.5, 15, 20, 25, 30 or 40 mg by a human patient. Most preferably unit doses contain 20 mg of active ingredient calculated on a free base basis. Such a composition is normally taken from 1 to 6 times daily, for example 2, 3 or 4 times daily so that the total amount of active agent administered is within the range 5 to 400 mg of active ingredient calculated on a free base basis. Most preferably the unit dose is taken once a day.
  • Preferred unit dosage forms include tablets or capsules, including formulations adapted for controlled or delayed release.
  • compositions of this invention may be formulated by conventional methods of admixture such as blending, filling and compressing.
  • Suitable carriers for use in this invention include a diluent, a binder, a disintegrant, a colouring agent, a flavouring agent and/or preservative. These agents may be utilized in conventional manner, for example in a manner similar to that already used for marketed anti-depressant agents.
  • compositions include those described EP-B-0223403, and US 4,007,196 in which the anhydrate product of the present invention may be used as the active ingredient. Accordingly, the present invention also provides:
  • compositions for treatment or prophylaxis of the disorders comprising paroxetine hydrochloride anhydrate obtainable by this invention and a pharmaceutically acceptable carrier;
  • paroxetine hydrochloride anhydrate obtainable by this invention to manufacture a medicament for the treatment or prophylaxis of the disorders
  • a method of treating the disorders which comprises administering an effective or prophylactic amount of paroxetine hydrochloride anhydrate obtainable by this invention to a person suffering from one or more of the disorders.
  • the invention is illustrated by the following Examples. In these Examples drying has been carried out under standardised conditions for the purpose of comparison. Conventionally prepared paroxetine hydrochloride acetone solvate contains approximately 6% acetone under these drying conditions. (20 hours at 60°C). Paroxetine hydrochloride with lower residual acetone for commercial use can be obtained by increasing the drying time or temperature.
  • Paroxetine hydrochloride (30 g) and acetone (870 ml) were charged to a 1 litre jacketed vessel equiped with a mechanical stirrer and a high intensity ultrasonic probe.
  • the mixture was stirred and heated to 56°C under a nitrogen atmosphere to afford a clear solution which was then allowed to cool to 49°C.
  • the solution was insonated (frequency 20 kHz, amplitude 12 microns) at this temperature for three minutes after which time the solution became cloudy.
  • the mixture was then cooled to ambient temperature, with continous insonation over a period of 40 minutes.
  • the product was collected by filtration and dried under vacuum at 60°C for 20 hours.
  • Weight of product 25.2g; acetone content 1.3% by weight; acicular crystals size 10 - 50 microns in length, no agglomeration. More than 50% of the sample consisted of crystals with a volume less than 200 cubic microns.
  • Paroxetine hydrochloride (29 g) and acetone (850 ml) were charged to a 1 litre jacketed vessel equiped with a mechanical stirrer and a high intensity ultrasonic probe. The mixture was stirred and heated to 56°C under a nitrogen atmosphere to afford a clear solution which was then allowed to cool to 50°C. The solution was insonated (frequency 20 kHz, amplitude 12 microns) for ten minutes with the temperature held betwwen 48-50°C. The mixture was then cooled with stirring to ambient temperature over a period of 35 minutes. The product was collected by filtration and dried under vacuum at 60°C for 20 hours. Weight of product 23.1 g; acetone content 2.0%. More than 50% of the sample consisted of crystals with a volume less than 1600 cubic microns.
  • Paroxetine hydrochloride (29 g) and acetone (850 ml) were charged to a 1 litre jacketed vessel equiped with a mechanical stirrer and a sonication probe. The mixture was stirred and heated to 56°C under a nitrogen atmosphere to afford a clear solution which was then allowed to cool to 50°C. The solution was insonated (frequency 20 kHz, amplitude 12 microns) for ten minutes with the temperature held betwwen 48-50°C. The mixture was then cooled with stirring to ambient temperature over a period of 35 minutes. The product was collected by filtration and dried under vacuum at 60°C for 20 hours. Weight of product 23.1 g (acetone content 2.0% by weight).

Abstract

Crystalline paroxetine hydrochloride acetone solvate having a modified habit that is more easily desolvated to form the anhydrate is obtained by crystallising from a solution of paroxetine hydrochloride in acetone under intense insonation conditions, or in a continuous crystalliser, or which has been seeded with crystals of a paroxetine hydrochloride solvate or anhydrate, especially Form A anhydrate.

Description

PROCESS FOR THE PREPARATION OF PAROXETINE HYDROCHLORIDE
The present invention relates to a process for the preparation of a pharmaceutically active compound and intermediates thereof, and to the use of the active compound in therapy. In particular this invention is concerned with a new process for the preparation of paroxetine chloride acetone solvate and its use to prepare a crystalline anhydrate form of paroxetine hydrochloride.
Pharmaceutical products with antidepressant and anti-Parkinson properties are described in US-A-3912743 and US-A-4007196. An especially important compound among those disclosed is paroxetine, the (-)trans isomer of 4-(4'-fluorophenyl)-3-(3',4'-methylenedioxy- phenoxymethyl)-piperidine. This compound is used in therapy as the hydrochloride salt for the treatment and prophylaxis of inter alia depression, obsessive compulsive disorder (OCD) and panic.
Paroxetine hydrochloride has been described in the literature as a crystalline hemihydrate (see EP-A-0223403 of Beecham Group) and as various crystalline anhydrate forms (see WO96/24595 of SmithKline Beecham). WO96/24595 describes the preparation of paroxetine hydrochloride acetone solvate which is a useful intermediate for the preparation of paroxetine hydrochloride anhydrate Form A. When prepared conventionally by crystallisation from anhydrous acetone, paroxetine hydrochloride acetone solvate has poor stirring properties, and is difficult to isolate, wash, and dry.
The desolvation of paroxetine hydrochloride acetone solvate has been described in WO 96/25495. It is clear from this publications that desolvation in a vacuum oven is a slow and difficult process. Furthermore, when operated on a scale larger than a few grammes, the time and temperature necessary for substantially complete desolvation increase very greatly. Lengthy treatment is undesirable for manufacturing because of the costs associated with vessel occupancy, and high temperatures cause degradation and phase transformation in the product. Another undesirable feature of the existing process is the tendency for the product to crystallise in a heavy matted form which is very difficult to stir, transfer, and filter. It is therefore evident that the existing process is unsuitable for the large scale manufacture of paroxetine hydrochloride. This invention provides processes for the preparation of paroxetine hydrochloride acetone solvate in a form which is more easily desolvated than paroxetine hydrochloride acetone solvate prepared in a conventional manner, and hence more suitable for commercial manufacturing processes.
According to one aspect of the present invention there is provided a process for preparing crystalline paroxetine hydrochloride acetone solvate which comprises providing a solution of paroxetine hydrochloride in acetone, and crystallising paroxetine hydrochloride acetone solvate under conditions of intense insonation.
Advantageously, insonation is carried out during slow cooling through the metastable zone, and is maintained during cooling to ambient temperature. These conditions provide a continuous flux of freshly generated nuclei, and result in crystallisation of paroxetine hydrochloride acetone solvate in a modified crystal habit which is easy to stir, wash and filter, and surprisingly is more readily desolvated than conventionally crystallised paroxetine hydrochloride acetone solvate.
Suitably crystallization is carried out in a vessel provided with one or more high intensity ultrasonic probes, for example with titanium alloy resonant horns which enable acoustic energy to be coupled to the crystallizing medium at a frequency of 20 kHz and an amplitude of 12 microns or more, and with a device that modifies the power output according to the acoustic parameters of the load. Insonation may be intermittent, limited to part of the apparatus, or discontinued once sufficient nuclei have been generated.
In another aspect of this invention, rapid crystallisation onto a dense flux of freshly generated nuclei may be achieved by causing rapid crystallisation in a continuous flow crystallisation apparatus. Suitably, the crystallisation may be achieved by bringing together two liquid streams, for example a solution of paroxetine hydrochloride in acetone and an anti-solvent such as hexane or heptane, or by rapid cooling of a single solvent stream, or by insonation of a saturated solvent stream, or by a combination of some or all of these techniques. In the case where two streams are combined, generation of nuclei and crystallisation takes place in a reaction zone, which may vary from a specially designed vortex mixer to a simple Y-tube.
According to another aspect of the present invention there is provided a process for crystallising paroxetine hydrochloride acetone solvate with modified habit from a solution of paroxetine hydrochloride in acetone in the presence of a dense flux of nuclei supplied by the addition of seeds. Suitable seeds are obtained from a wide range of paroxetine hydrochloride solvates such as, for example, the solvate with pyridine, acetic acid, p- xylene, N.N'-dimethylformamide, chloroform, dichloromethane. dichloroethane, acetonitrile, propan-1 -ol, ethanol, acetone, acetone, tetrahydrofuran, 1,4-dioxane, or the Form "A" anhydrate. Advantageously seeding is carried out with very finely powdered paroxetine hydrochloride anhydrate or solvate at elevated temperature. The seeds should preferably be less than 30 microns in length, and median particle volume below 120 cubic microns. Seeding should preferably be carried out within the metastable zone.
The efficiency of external seeding may be greatly increased by very vigorous stirring, since secondary nuclei are generated by attrition of larger seed crystals, resulting in an increased flux of suitable nuclei. In certain cases a suffficient flux of nuclei may be generated by particularly vigorous stirring alone, although this procedure is unlikely to be as effective unless the crystallisation vessel is routinely used for the crystallisation of paroxetine hydrochloride acetone solvate and so is in effect saturated with seed crystals. Suitable apparatus includes stirrers designed to operate at high torque with high shear rate and vessels with optimal hydrodynamic design including the use of baffles and bladed stirrers.
These procedures for crystallisation in a flux of freshly generated nuclei modify the habit of the resultant crystals to a form which allows more effective de-solvation of the crystals. Furthermore, the procedures result in a controlled crystallisation in which the product can be stirred efficiently and continuously without the use of specialised apparatus, and without forming dense unstirrable zones in the crystallizer. A suitable concentration of paroxetine hydrochloride in acetone is one part in from 4 to 40 volumes of acetone, preferably from 10 to 30 volumes, and more preferably from 15 to 25 volumes. Preferably the acetone is anhydrous to suppress formation of paroxetine hydrochloride hemihydrate.
The preparation of crystalline paroxetine hydrochloride anhydrate, for use as seed crystals in one of the processes of this invention, is described in WO 96/24595.
Suitable procedures for preparing paroxetine hydrochloride for dissolution in acetone for use in the process of this invention include those mentioned in US Patents 4.009.196; 4,721,723; 4,902,801 ; 4,861,893 and 5,039,803.
In addition to the procedures described above, crystallisation may be assisted by conventional techniques such as cooling, or removing solvent by evaporation or distillation.
The crystalline paroxetine hydrochloride acetone solvate of modified crystal habit obtainable by the process of this invention is a different crystalline form from the previously known product. This novel product forms another aspect of this invention.
One characteristic in which the new form differs from the previously known form is in the particle size distribution and mean particle volume. Paroxetine hydrochloride acetone solvate crystals prepared conventionally are large and long, typically with most of the material in the form of crystals in excess of 300 microns in length, with a length-to-width ratio in excess of 40: 1 , and a volume by for example laser light scattering, of 20,000 cubic microns or more. By contrast in the novel form of paroxetine hydrochloride acetone solvate, most of the material is in crystals less than 100 microns long, preferably below 75 microns, and more preferably below 50 microns, and with a length-to-width ratio below 20:1, preferably below 15:1 and more preferably below 10: 1, and with a volume below 5,000 cubic microns, preferably below 2,500 cubic microns and more preferably below
3,000 cubic microns. The product of this invention may have either one, two or all three of these desirable characteristics. During the course of our investigations we have discovered that one particular crystallographic axis is critical to the rapid desolvation of paroxetine hydrochloride acetone solvate. Hence, in another aspect of this invention there is provided paroxetine hydrochloride acetone solvate of modified habit in which the mean distance between crystal facets characterised by the Miller indices (0, 1, 0) and (0, ~ι , 0) in a monoclinic crystal system. P2, space group is minimised, and is preferably below 100 microns.
It has been found that paroxetine hydrochloride acetone solvate with these characteristics may be processed and desolvated more easily than conventionally produced paroxetine hydrochloride acetone solvate.
The crystallisation process may include if necessary isolating the crystals, optionally washing and drying to remove surface solvent. However advantageously the crystalline solvate is used as a feed material for desolvation to obtain paroxetine hydrochloride anhydrates, especially the Form A anhydrate.
Accordingly, in a further aspect the present invention provides a process for preparing a crystalline anhydrate of paroxetine hydrochloride by heating crystalline acetone solvate obtainable by the process of this invention to remove bound acetone.
Desolvation is conveniently carried out by heating in an oven, preferably in vacuo, suitably at a temperature of about 60°C.
The resultant anhydrate desirably contains less than 3% of acetone, preferably less than 1%, more preferably less than 0.5%, and most preferably less than 0.1%. Advantageously the crystalline anhydrate is the Form A anhydrate of paroxetine hydrochloride.
The crystalline paroxetine hydrochloride anhydrate obtainable by this invention may be used in therapy in formulations described in EP-A-0223403 or WO 96/00477.
Therapeutic uses of the paroxetine hydrochloride anhydrate of this invention include treatment of: alcoholism, anxiety, depression, obsessive compulsive disorder (OCD), panic disorder, chronic pain, obesity, senile dementia, migraine, bulimia, anorexia, social phobia, pre-menstrual syndrome (PMS), adolescent depression, trichotillomania. dysthymia, and substance abuse, referred to below as "the disorders".
Most suitably the anhydrate obtainable by the present invention is applied to the treatment of depression, OCD and panic.
The compositions prepared in accordance with this invention are usually adapted for oral administration, but formulations for dissolution for parental administration are also within the scope of this invention.
The composition is usually presented as a unit dose composition containing from 1 to 200 mg of active ingredient calculated on a free base basis, more usually from 5 to 100 mg, for example 10 to 50mg such as 10, 12.5, 15, 20, 25, 30 or 40 mg by a human patient. Most preferably unit doses contain 20 mg of active ingredient calculated on a free base basis. Such a composition is normally taken from 1 to 6 times daily, for example 2, 3 or 4 times daily so that the total amount of active agent administered is within the range 5 to 400 mg of active ingredient calculated on a free base basis. Most preferably the unit dose is taken once a day.
Preferred unit dosage forms include tablets or capsules, including formulations adapted for controlled or delayed release.
The compositions of this invention may be formulated by conventional methods of admixture such as blending, filling and compressing. Suitable carriers for use in this invention include a diluent, a binder, a disintegrant, a colouring agent, a flavouring agent and/or preservative. These agents may be utilized in conventional manner, for example in a manner similar to that already used for marketed anti-depressant agents.
Specific examples of pharmaceutical compositions include those described EP-B-0223403, and US 4,007,196 in which the anhydrate product of the present invention may be used as the active ingredient. Accordingly, the present invention also provides:
a pharmaceutical composition for treatment or prophylaxis of the disorders comprising paroxetine hydrochloride anhydrate obtainable by this invention and a pharmaceutically acceptable carrier;
the use of paroxetine hydrochloride anhydrate obtainable by this invention to manufacture a medicament for the treatment or prophylaxis of the disorders; and
a method of treating the disorders which comprises administering an effective or prophylactic amount of paroxetine hydrochloride anhydrate obtainable by this invention to a person suffering from one or more of the disorders.
The invention is illustrated by the following Examples. In these Examples drying has been carried out under standardised conditions for the purpose of comparison. Conventionally prepared paroxetine hydrochloride acetone solvate contains approximately 6% acetone under these drying conditions. (20 hours at 60°C). Paroxetine hydrochloride with lower residual acetone for commercial use can be obtained by increasing the drying time or temperature.
Example 1
Paroxetine hydrochloride (30 g) and acetone (870 ml) were charged to a 1 litre jacketed vessel equiped with a mechanical stirrer and a high intensity ultrasonic probe. The mixture was stirred and heated to 56°C under a nitrogen atmosphere to afford a clear solution which was then allowed to cool to 49°C. The solution was insonated (frequency 20 kHz, amplitude 12 microns) at this temperature for three minutes after which time the solution became cloudy. The mixture was then cooled to ambient temperature, with continous insonation over a period of 40 minutes.The product was collected by filtration and dried under vacuum at 60°C for 20 hours. Weight of product 25.2g; acetone content 1.3% by weight; acicular crystals size 10 - 50 microns in length, no agglomeration. More than 50% of the sample consisted of crystals with a volume less than 200 cubic microns.
Example 2
Paroxetine hydrochloride (29 g) and acetone (850 ml) were charged to a 1 litre jacketed vessel equiped with a mechanical stirrer and a high intensity ultrasonic probe. The mixture was stirred and heated to 56°C under a nitrogen atmosphere to afford a clear solution which was then allowed to cool to 50°C. The solution was insonated (frequency 20 kHz, amplitude 12 microns) for ten minutes with the temperature held betwwen 48-50°C. The mixture was then cooled with stirring to ambient temperature over a period of 35 minutes.The product was collected by filtration and dried under vacuum at 60°C for 20 hours. Weight of product 23.1 g; acetone content 2.0%. More than 50% of the sample consisted of crystals with a volume less than 1600 cubic microns.
Example 3
Paroxetine hydrochloride (29 g) and acetone (850 ml) were charged to a 1 litre jacketed vessel equiped with a mechanical stirrer and a sonication probe. The mixture was stirred and heated to 56°C under a nitrogen atmosphere to afford a clear solution which was then allowed to cool to 50°C. The solution was insonated (frequency 20 kHz, amplitude 12 microns) for ten minutes with the temperature held betwwen 48-50°C. The mixture was then cooled with stirring to ambient temperature over a period of 35 minutes. The product was collected by filtration and dried under vacuum at 60°C for 20 hours. Weight of product 23.1 g (acetone content 2.0% by weight).

Claims

1. A process for obtaining crystalline paroxetine hydrochloride acetone solvate which comprises providing a solution of paroxetine hydrochloride in acetone, and crystallising paroxetine hydrchloride acetone solvate under conditions of intense insonation.
2. A process according to claim 1 in which the insonation is carried out during slow cooling through the metastable zone, and is maintained during cooling to ambient temperature.
3. A process according to claims 1 or 2 in which the crystallization is carried out in a vessel provided with one or more high intensity ultrasonic probes, for example with titanium alloy resonant horns which enable acoustic energy to be coupled to the crystallizing medium at a frequency of 20 kHz and an amplitude of 12 microns or more, and with a device that modifies the power output according to the acoustic parameters of the load.
4. A process according to claims 1, 2, or 3 in which the insonation is intermittent or limited to part of the apparatus, or discontinued once sufficient nuclei have been generated.
5. A process for obtaining crystalline paroxetine hydrochloride acetone solvate which comprises providing a solution of paroxetine hydrochloride in acetone, and crystallising paroxetine hydrchloride acetone solvate in a continuous flow crystallisation apparatus.
6. A process according to claim 5 in which the crystallisation is achieved by bringing together two liquid streams, such as a solution of paroxetine hydrochloride in acetone and an anti-solvent such as hexane or heptane.
7. A process according to claim 5 in which the crystallisation is achieved by rapid cooling of a single solvent stream, or by insonation of a saturated solvent stream.
8. A process according to claim 5, 6, or 7 in which the crystallisation takes place in a reaction zone, such as a vortex mixer or a Y-tube.
9. A process for obtaining crystalline paroxetine hydrochloride acetone solvate which comprises providing a solution of paroxetine hydrochloride in acetone, and crystallising paroxetine hydrchloride acetone solvate in the presence of crystallisation nuclei supplied by the addition of seeds.
10. A process according to claim 9 in which the seeds are obtained from paroxetine hydrochloride solvates with pyridine, acetic acid, p-xylene, N-N'-dimethylformamide, chloroform, dichloromethane, dichloroethane, acetonitrile, propan-1-ol. ethanol, acetone, acetone, tetrahydrofuran, or 1,4-dioxane, or the Form "A" anhydrate.
1 1. A process according to claims 9 or 10 in which the seed is very finely powdered.
12. A process according to claims 9, 10, or 11 in which the finely powdered seed consists mainly of crystals less than 30 microns in length or median particle volume below 120 cubic microns.
13. A process according to claims 9, 10, 11, or 12 in which seeding is carried out within the metastable zone.
14. A process according to claims 9 to 13 in which seeding and crystallisation is carried out at a temperature of from 40 to 70°C, more preferably from 55 to 65°C, and optimally from 58 to 62°C.
15. A process according to any of claims 1 to 14 in which nucleation is augmented by very vigorous stirring.
16. A process for obtaining crystalline paroxetine hydrochloride acetone solvate which comprises providing a solution of paroxetine hydrochloride in acetone , and generating crystallisation nuclei by very vigorous stirring in a vessel previously used for the preparation of paroxetine hydrochloride acetone solvate.
17. A process according to claim 16 in which the apparatus includes stirrers designed to operate at high torque with high shear rate and vessels with optimal hydrodynamic design including the use of baffles and bladed stirrers.
18. Crystalline paroxetine hydrochloride acetone solvate of modified crystal habit obtainable by a process according to any of claims 1 to 17.
19. A process according to claims 1 to 17 for the production of paroxetine hydrochloride acetone solvate from which more than 50% by weight of the product consists of crystals in which the distance between the facets with Miller indices (0, 1, 0) and (0, 1, 0) in a monoclinic crystal system, P2, space group, is less than 100 microns.
20. Crystalline paroxetine hydrochloride acetone solvate of modified crystal habit in which more than 50% by weight of the material is in crystals less than 100 microns long, preferably below 75 microns, and more preferably below 50 microns.
21 Crystalline paroxetine hydrochloride acetone solvate of modified crystal habit in which more than 50% by weight of the material is in crystals with a length-to-width ratio below 20:1, preferably below 15:1 and more preferably below 10:1.
22. Crystalline paroxetine hydrochloride acetone solvate of modified crystal habit in which more than 50% by weight of the material is in crystals with a volume below 5,000 cubic microns, preferably below 2,500 cubic microns and more preferably below 1 ,000 cubic microns.
23. Crystalline paroxetine hydrochloride acetone solvate of modified crystal habit in which the distance between crystal facets characterised by the Miller indices (0, 1, 0) and (0, 1, 0) in a monoclinic crystal system, P2, space group, is below 100 microns for more than 50% by weight of the product.
24. A process for preparing a crystalline anhydrate of paroxetine hydrochloride by heating crystalline acetone solvate obtainable by the process of claim 1 to 17 or 19 to remove bound acetone
5
25. A pharmaceutical composition for treatment or prophylaxis of the disorders comprising paroxetine hydrochloride anhydrate obtainable by the process of claim 1 to 17 or 19 and a pharmaceutically acceptable carrier;
10 26. Use of paroxetine hydrochloride anhydrate obtainable by the process of claim 1 to 17 or 19 to manufacture a medicament for the treatment or prophylaxis of the disorders; and
27. A method of treating the disorders which comprises administering an effective or prophylactic amount of paroxetine hydrochloride anhydrate obtainable by the process of
15 claim 1 to 17 or 19 to a person suffering from one or more of the disorders.
28. Paroxetine hydrochloride acetone solvate that is more easily desolvated, such that in a drying comparison with conventionally crystallised paroxetine hydrochloride acetone solvate under standard drying conditions, retains less than 75% of the acetone in the
20 standard, preferably less than 50%, and more preferably less than 25%.
29. The process of drying paroxetine hydrochloride acetone solvate claimed in or prepared _ by the processes claimed in any of the above claims.
PCT/GB1999/003961 1998-11-28 1999-11-26 Process for the preparation of paroxetine hydrochloride WO2000032591A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU13964/00A AU1396400A (en) 1998-11-28 1999-11-26 Process for the preparation of paroxetine hydrochloride

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9826175.3 1998-11-28
GBGB9826175.3A GB9826175D0 (en) 1998-11-28 1998-11-28 Novel process

Publications (1)

Publication Number Publication Date
WO2000032591A1 true WO2000032591A1 (en) 2000-06-08

Family

ID=10843287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/003961 WO2000032591A1 (en) 1998-11-28 1999-11-26 Process for the preparation of paroxetine hydrochloride

Country Status (3)

Country Link
AU (1) AU1396400A (en)
GB (1) GB9826175D0 (en)
WO (1) WO2000032591A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1256558A2 (en) * 2001-05-11 2002-11-13 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for producing crystals from propellants, explosives and oxidizers dissolved in a solvent
US6482438B1 (en) 1998-12-24 2002-11-19 Smithkline Beecham Corporation Apparatus and process for preparing crystalline particles
WO2003097095A1 (en) * 2002-05-20 2003-11-27 Chemstop Pty Ltd Process for the preparation and activation of substances and a means of producing same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0223403A2 (en) * 1985-10-25 1987-05-27 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
WO1995025732A1 (en) * 1994-03-18 1995-09-28 Ferrer Internacional, S.A. N-p-HALOBENZOYLMETHYL DERIVATIVES OF 4-(p-FLUOROPHENYL)-3-((3,4-METHYLENE-DIOXY)PHENOXY)METHYL)PIPERIDINE
WO1996024595A1 (en) * 1995-02-06 1996-08-15 Smithkline Beecham Plc New forms of paroxetin hydrochloride
WO1996036636A1 (en) * 1995-05-17 1996-11-21 Novo Nordisk A/S Process for preparing 4-aryl-piperidine derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0223403A2 (en) * 1985-10-25 1987-05-27 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
WO1995025732A1 (en) * 1994-03-18 1995-09-28 Ferrer Internacional, S.A. N-p-HALOBENZOYLMETHYL DERIVATIVES OF 4-(p-FLUOROPHENYL)-3-((3,4-METHYLENE-DIOXY)PHENOXY)METHYL)PIPERIDINE
WO1996024595A1 (en) * 1995-02-06 1996-08-15 Smithkline Beecham Plc New forms of paroxetin hydrochloride
WO1996036636A1 (en) * 1995-05-17 1996-11-21 Novo Nordisk A/S Process for preparing 4-aryl-piperidine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BUXTON P C ET AL: "SOLID-STATE FORMS OF PAROXETINE HYDROCHLORIDE", INTERNATIONAL JOURNAL OF PHARMACEUTICS,NL,AMSTERDAM, vol. 42, pages 135-143, XP000572028, ISSN: 0378-5173 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482438B1 (en) 1998-12-24 2002-11-19 Smithkline Beecham Corporation Apparatus and process for preparing crystalline particles
EP1256558A2 (en) * 2001-05-11 2002-11-13 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for producing crystals from propellants, explosives and oxidizers dissolved in a solvent
EP1256558A3 (en) * 2001-05-11 2004-12-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for producing crystals from propellants, explosives and oxidizers dissolved in a solvent
WO2003097095A1 (en) * 2002-05-20 2003-11-27 Chemstop Pty Ltd Process for the preparation and activation of substances and a means of producing same

Also Published As

Publication number Publication date
GB9826175D0 (en) 1999-01-20
AU1396400A (en) 2000-06-19

Similar Documents

Publication Publication Date Title
US6063927A (en) Paroxetine derivatives
JPH11509230A (en) Crystalline [R- (R ▲ *, R ▲ *))-2- (4-fluorophenyl) -β, δ-dihydroxy-5- (1-methylethyl) -3-phenyl-4 -[(Phenylamino) carbonyl] -1H-pyrrole-1-heptanoic acid hemicalcium salt (atorvastatin)
WO2000032597A1 (en) Process for the production of paroxetine hydrochloride propan-2-ol solvate
US20030203937A1 (en) Novel compound
WO2000032591A1 (en) Process for the preparation of paroxetine hydrochloride
WO2000035873A1 (en) Process for preparation of paroxetine maleate
EP1155016A1 (en) Process for the production of paroxetine hydrochloride acetone solvate
JP2002531450A (en) Process for producing paroxetine hydrochloride
JP2002531452A (en) Mixed paroxetine propan-2-ol solvate
CA2323896A1 (en) Crystalline form of paroxetine
WO2001012623A1 (en) Process for the preparation of paroxetine hydrochloride
CZ20003343A3 (en) Crystalline form of paroxetine
WO2000078752A1 (en) Process for the production of paroxetine hydrochloride
WO2001025231A1 (en) Process for the preparation of paroxetine hydrochloride acetone solvate
IES83541Y1 (en) Paroxetine methanesulfonate

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 13964

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase